Newer variant of the SARS-CoV-2 Omicorn family, named BA.4 and BA.5, is spreading rapidly through the globe and outcompeting the infectious speed of previous subvariants.

To keep our promise of continued contributions to the global fight against the pandemic, Pluslife Biotech has finished a series of validations on the Pluslife SARS-CoV-2 Nucleic Acid Testing Cards to ensure its effective performance to the virus development over time.

As a result, Pluslife testing cards can accurately detect Omicron BA.4, BA.5 and all other reported SARS-CoV-2 variants, achieving no false-negative results or off-target situations. 

Pluslife will continue to track and monitor the pandemic situation to ensure the product‘s specificity and sensitivity are maintained to reinforce the control and prevention of COVID-19.